Diabetes Management Market By Device Type, (Monitoring Devices, Diagnostic Devices, Insulin Delivery Devices), By Therapeutics, (Injectable, Oral Drugs), Industry analysis, Trends, Estimation & forecast, 2016 - 2024

  • Published On: Feb, 2019
  • Category: Healthcare
  • Pages: 0
This report studies Diabetes Management in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2011 to 2015, and forecast to 2025.

The term diabetes is referred to a disease which reduces the capability of the body to produce or respond to the hormone insulin, resulting in abnormal metabolism of carbohydrates and elevated levels of glucose in the blood. Scientifically, diabetes is also known as mellitus, and is classified as disorganization of pancreases to produce insulin (Type I) and unresponsiveness of body cells to the produced insulin (Type II) or both. This illness specifically results in increase in thrust and hunger. The cases of type II diabetes are majorly witnessed all around the world as a result of increased obesity, urbanization, poor diet and substandard healthcare conditions. The main goal of diabetes management is, as soon as possible, to restore carbohydrate metabolism to a normal state. The global market for diabetes is extremely profitable for drug and device manufacturers as treatment majorly demands therapeutic and diagnostic management.

Diabetes Management Market Determinants

The key factor driving the growth of global diabetes management market is the increasing diabetic patients and increasing healthcare awareness. As per the data revealed by National Diabetes Statistics Report, in 2015, an estimated 23.1 million people, or 7.2% of the U.S. population had diagnosed diabetes. Moreover, increase in collaborations & associations are creating better avenues to attain high effectiveness. In addition to this, increasing occurrence of type I and type II diabetes as a result of high obese population is highly stimulating the market growth. However, high costs related to diabetes management, limited infrastructure for management and counterfeiting of drugs are major restraining factors for global diabetes management market. On the other hand, developing economies are expected to provide huge growth potential for the market, during the few years.

Diabetes Management Market Segmentation

• By Device Type  o Monitoring Devices o Blood Glucose Meters o Lancets o Blood Sampling Devices o Diagnostic Devices o Hemoglobin A1c o Hemoglobin A1c Kits o Hemoglobin A1c Meters o Insulin Delivery Devices o Insulin Pumps o Insulin Pens o Disposable Insulin Pens o Insulin Syringes o Reusable Insulin Pens o Others (artificial pancreas, artificial pancreas, commercial software) • By Therapeutics o Injectable o Insulin o Exenatide o Oral Drugs Sulfonylureas o Metformin o Alpha-Glucosidase Inhibitors o Meglitinides o Dipeptidyl Inhibitors o Thiazolidinedione o Combination Medications • By Geography o North America o Europe o Asia-Pacific o Rest of World

Table of Content

• Abbott Laboratories
• Dexcom
• Novo Nordisk A/S
• Bristol-Myers Squibb
• Eli Lilly and Co.
• Bayer AG
• Medtronic
• Abbott

Select License Type

  • $4700
  • $5600
  • $2000
  • Buy Now

Report Highlights:

Complete overview of market
Major drivers, restrain, opportunities, and challenges of the market
Market Trends and how they are boosting the market growth
Changing dynamics in the Market
Complete overview of the market
Historical, Base year, projected, and current market size in terms of value and volume
COVID-19 Impact analysis of the market
Current industry trends and developments

CLIENTS